Autophagy Dysregulation in Diabetic Kidney Disease: From Pathophysiology to Pharmacological Interventions

Claudio D Gonzalez1,2, María Paula Carro Negueruela2, Catalina Nicora Santamarina2

  • 1Instituto de Bioquimica y Medicina Molecular Prof. Alberto Boveris (UBA-CONICET), Facultad de Farmacia y Bioquimica, Universidad de Buenos Aires, Buenos Aires C1113 AAD, Argentina.

Cells
|September 28, 2021
PubMed

Insights

Diabetic kidney disease (DKD) involves cellular damage due to altered autophagy. Modulating autophagy shows promise for treating and preventing DKD, requiring further research.

Area of Science:

  • Cellular Biology
  • Nephrology
  • Endocrinology

Background:

  • Diabetic kidney disease (DKD) is a major complication of diabetes mellitus, characterized by cellular structural and functional alterations.
  • Autophagy, a cellular process crucial for homeostasis, is profoundly dysregulated in DKD, impacting disease progression and severity.

Purpose of the Study:

  • To explore the intricate relationship between autophagy and the pathophysiology of diabetic kidney disease.
  • To evaluate the potential of modulating autophagy as a therapeutic strategy for DKD.

Main Methods:

  • Review of existing literature on autophagy mechanisms in DKD models.
  • Analysis of studies investigating the effects of antidiabetic agents and other drugs on autophagy in DKD.

Main Results:

  • DKD is associated with significant alterations in autophagy rate and flux.
  • Certain antidiabetic agents impact autophagy and have shown potential to improve patient outcomes.
  • Emerging therapies targeting autophagy are under investigation for DKD treatment.

Conclusions:

  • Autophagy dysregulation is a key feature of diabetic kidney disease.
  • Targeting autophagy presents a promising avenue for future pharmacological interventions in DKD prevention and treatment.
  • Further experimental and clinical research is essential to fully realize the therapeutic potential of autophagy modulation in DKD.

Related Concept Videos

Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
2.1K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
570
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
192
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
133
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
27
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
24